Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I6/383

[1] 国家食品药品监督管理局药品安全监管司, 国家药品不良反应中心. 药品不良反应报告和监测工作手册[S]. 2005: 46.
[2] 刘敏, 李忠东. 实例探讨药物引起SJS或TEN的评分方法—Naranjo评分与ALDEN评分比较[J]. 中国药物应用与监测, 2014, 11(4):247-249.
[3] 张纾,林强, 林小燕, 等. 疑似低分子右旋糖酐氨基酸注射液诱发急性左心衰竭致死之1例[J]. 中国药物警戒. 2013, 10(6):381-382.
[4] 戈特曼. 治疗学药理基础[M]. 北京:人民卫生出版社, 1987:777.
[5] 陈浩涛,王娟,吴珊珊.低分子右旋糖酐氨基酸注射液致过敏反应一例[J]. 临床合理用药杂志, 2012, 5(1):124.
[6] 高继敬,李成建. 低分子右旋糖酐氨基酸注射液所致过敏反应文献概述[J]. 中国药物滥用防治杂志, 2015, 21(3):174-175.
[7] 李婷, 瞿慧君, 卫英. 低分子右旋糖酐氨基酸注射液致过敏性休克一例[J]. 药学服务与研究, 2012, 12(3):240.
[8] 刘歌. 低分子右旋糖酐不良反应的观察与护理[J]. 中国社区医师, 2011, 13(4):197.
[9] 杨德平. 154例舒血宁注射液的严重不良反应分析[J]. 中国药物警戒, 2010, 7(10):620-622.
[10]管玫, 金朝辉, 杨娟. 282例左氧氟沙星不良反应报告分析[J]. 中国药物警戒, 2007, 4(3):158-161.
[11]张莉, 段小菊, 王哲, 等. 低分子右旋糖酐氨基酸注射液致严重过敏性休克1例[J]. 中国药物应用与监测, 2016,13(1):56-58.
[12] 陈雪梅, 金国栋, 杜微微. 低分子右旋糖酐注射液的不良反应报告[J]. 北方药学, 2013, 10(9):40.
[13] 许金为, 赖有莲, 林芬月. 低分子右旋糖酐不良反应致死1例[J]. 中国实用医药, 2009, 4(32):146-147.
[14] 陈红梅.低分子右旋糖酐不良反应1例临床急救[J]. 齐鲁护理杂志, 2008, 14(19): 26.
[15] 李寅, 孙成荣. 低分子右旋糖酐与呋塞米联用致不良反应1例[J]. 中国药物应用与监测, 2014, 11(2):129-130.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913.
[2]	QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727.
[3]	LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
[4]	ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
[5]	LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793.
[6]	LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569.
[7]	YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
[8]	LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285.
[9]	ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192.
[10]	LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
[11]	SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414.
[12]	ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024.
[13]	YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028.
[14]	SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899.
[15]	WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.